TCRT
ALAUNOS (TCRT)
NASDAQ
$1.84+$0.08 (+4.49%)
Price as of Aug 21, 2026 7:05 PM EDT
  • $4.3M
    Market Cap
  • -0.56%
    1-Year Change
  • Biotechnology
    Industry

Key Performance

More
  • Earnings Score: N/A
  • Momentum Score: 46
  • True Yield: N/A
  • Financial Health Score: N/A
TradeSmith Loading

Latest Research & News

No data found

No data found

Peers

Statistics

More
Day Range
$1.73
$1.84
$1.76
1-Year Range
$1.76
$4.36
$1.76
Latest Close$1.76
Change
-$0.04 (-2.27%)
Volume16,142
Market Cap$4.3M
Shares Outstanding2.4M
P/E (TTM)-0.97
Diluted EPS (TTM)-$1.81
Enterprise Value$4.2M

Information as of 08/21/2026

Company Profile

ALAUNOS THERAPEUTICS INC
ALAUNOS THERAPEUTICS INC
https://www.alaunos.com
$4.3M
Market Cap
-$4.0M
Net Income
Sector: Healthcare
Industry: Biotechnology
501 E. Las Olas Blvd., Fort Lauderdale, FL, United States, 33301
346 355 4099

Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida.

Key Executives

  • Holger Weis
  • Ferdinand Groenewald

Current Ownership Distribution

  • Institutions572.0M (78.40%)
  • Mutual Funds152.6M (20.92%)
  • Insiders5.0M (0.68%)
  • Other0 (0.00%)